Foco neurológico en paciente pediátrico con leucemia linfoblástica aguda

Se describe el caso de un paciente pediátrico con leucemia linfoblástica aguda T (LLA-T) que durante su tratamiento presenta síntomas neurológicos como efecto adverso asociado a la quimioterapia.Se discuten los posibles diagnósticos diferenciales, diagnóstico y conducta terapéutica a seguir.

[1]  R. Bansal,et al.  Managing therapy-associated neurotoxicity in children with ALL. , 2021, Hematology. American Society of Hematology. Education Program.

[2]  G. Chenevix-Trench,et al.  Methotrexate-related central neurotoxicity: clinical characteristics, risk factors and genome-wide association study in children treated for acute lymphoblastic leukemia , 2021, Haematologica.

[3]  T. Foiadelli,et al.  Posterior Reversible Encephalopathy Syndrome in infants and young children. , 2020, European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.

[4]  Amal Refaat,et al.  Patterns, risk factors and outcome predictors of posterior reversible encephalopathy syndrome in pediatric cancer patients , 2020, Leukemia & lymphoma.

[5]  P. Lähteenmäki,et al.  The spectrum of acute central nervous system symptoms during the treatment of childhood acute lymphoblastic leukaemia , 2020, Pediatric blood & cancer.

[6]  Elias B Rizk,et al.  Posterior reversible encephalopathy syndrome in pediatric patients: pathophysiology, diagnosis, and management , 2019, Leukemia & lymphoma.

[7]  K. Schmiegelow,et al.  Posterior reversible encephalopathy syndrome in children with acute lymphoblastic leukemia: Clinical characteristics, risk factors, course, and outcome of disease , 2019, Pediatric blood & cancer.

[8]  Austin L. Brown,et al.  Disparities in Neurotoxicity Risk and Outcomes among Pediatric Acute Lymphoblastic Leukemia Patients , 2018, Clinical Cancer Research.

[9]  R. Hanada,et al.  Characteristics of methotrexate-induced stroke-like neurotoxicity , 2018, International Journal of Hematology.

[10]  H. Marquart,et al.  Thromboembolism in acute lymphoblastic leukemia: results of NOPHO ALL2008 protocol treatment in patients aged 1 to 45 years. , 2018, Blood.

[11]  P. Zubizarreta,et al.  Acute and sub-acute neurological toxicity in children treated for acute lymphoblastic leukemia. , 2018, Leukemia research.

[12]  A. Vora,et al.  Cerebral sinovenous thrombosis in children and young adults with acute lymphoblastic leukaemia – a cohort study from the United Kingdom , 2017, British journal of haematology.

[13]  I. Cohen.  Neurotoxicity after high-dose methotrexate (MTX) is adequately explained by insufficient folinic acid rescue , 2017, Cancer Chemotherapy and Pharmacology.

[14]  L. Silverman,et al.  Consensus definitions of 14 severe acute toxic effects for childhood lymphoblastic leukaemia treatment: a Delphi consensus. , 2016, The Lancet. Oncology.

[15]  N. Hijiya,et al.  Rechallenging With Intrathecal Methotrexate After Developing Subacute Neurotoxicity in Children With Hematologic Malignancies , 2016, Pediatric blood & cancer.

[16]  Salih Güler,et al.  Acute Central Nervous System Complications in Pediatric Acute Lymphoblastic Leukemia. , 2015, Pediatric neurology.

[17]  A. Rabinstein,et al.  Posterior reversible encephalopathy syndrome: clinical and radiological manifestations, pathophysiology, and outstanding questions , 2015, The Lancet Neurology.

[18]  Antonio Greco,et al.  Posterior reversible encephalopathy syndrome--Insight into pathogenesis, clinical variants and treatment approaches. , 2015, Autoimmunity reviews.

[19]  J. Downing,et al.  Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  M. Heyman,et al.  Cerebral sinus venous thromboses in children with acute lymphoblastic leukaemia – a multicentre study from the Nordic Society of Paediatric Haematology and Oncology , 2015, British journal of haematology.

[21]  M. Relling,et al.  Methotrexate-induced neurotoxicity and leukoencephalopathy in childhood acute lymphoblastic leukemia. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  J. Bond,et al.  ‘Stroke-like syndrome’ caused by intrathecal methotrexate in patients treated during the UKALL 2003 trial , 2013, Leukemia.

[23]  Jae Wook Lee,et al.  Predisposing factors of posterior reversible encephalopathy syndrome in acute childhood leukemia. , 2012, Pediatric neurology.

[24]  Qing Liu,et al.  The Clinical and Radiological Spectrum of Posterior Reversible Encephalopathy Syndrome: A Retrospective Series of 24 Patients , 2011, Journal of neuroimaging : official journal of the American Society of Neuroimaging.

[25]  V. Poggi,et al.  Central nervous system complications during treatment of acute lymphoblastic leukemia in a single pediatric institution , 2010, Leukemia & lymphoma.

[26]  S. Richards,et al.  Asparaginase‐related venous thrombosis in UKALL 2003‐ re‐exposure to asparaginase is feasible and safe , 2010, British journal of haematology.

[27]  G. Kenet,et al.  Thrombosis in childhood acute lymphoblastic leukaemia: epidemiology, aetiology, diagnosis, prevention and treatment. , 2009, Best practice & research. Clinical haematology.

[28]  V. Vijayanathan,et al.  Folate homeostasis in cerebrospinal fluid during therapy for acute lymphoblastic leukemia. , 2009, Pediatric neurology.

[29]  Charles L Truwit,et al.  Posterior reversible encephalopathy syndrome: incidence of atypical regions of involvement and imaging findings. , 2007, AJR. American journal of roentgenology.

[30]  L. Iacoviello,et al.  Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients. , 2006, Blood.

[31]  G. Masera,et al.  Ischemic Stroke in Children Treated for Acute Lymphoblastic Leukemia: A Retrospective Study , 2005, Journal of pediatric hematology/oncology.

[32]  N. Winick,et al.  Acute methotrexate neurotoxicity: findings on diffusion-weighted imaging and correlation with clinical outcome. , 2004, AJNR. American journal of neuroradiology.

[33]  N. Winick,et al.  Effects of Intraventricular Methotrexate on Folate, Adenosine, and Homocysteine Metabolism in Cerebrospinal Fluid , 2004, Journal of pediatric hematology/oncology.

[34]  E. Cook,et al.  Homocysteine, pharmacogenetics, and neurotoxicity in children with leukemia. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  I. Grunwald,et al.  [Stroke in childhood]. , 2003, Der Radiologe.

[36]  Anthony K. C. Chan,et al.  Thrombosis in children with acute lymphoblastic leukemia Part III. Pathogenesis of thrombosis in children with acute lymphoblastic leukemia: effects of host environment. , 2003, Thrombosis research.

[37]  R. Meuli,et al.  Diagnosis of Cerebral Venous Thrombosis with Routine Magnetic Resonance: An Update , 1998, European Neurology.

[38]  C. Pui,et al.  Transient encephalopathy following high-dose methotrexate treatment in childhood acute lymphoblastic leukemia , 1998, Leukemia.

[39]  N. Winick,et al.  Acute neurotoxicity in children with B-precursor acute lymphoid leukemia: an association with intermediate-dose intravenous methotrexate and intrathecal triple therapy--a Pediatric Oncology Group study. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  T. Bottiglieri,et al.  Elevation of homocysteine and excitatory amino acid neurotransmitters in the CSF of children who receive methotrexate for the treatment of cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.